Provider Alert! Pegfilgrastim-cbqv (Udenyca) to be Diagnosis Restricted Effective May 1, 2022Texas Children's Health Plan
Date: July 1, 2022
Attention: All Providers
Effective Date: May 1, 2022
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective for dates of service on or after May 1, 2022, pegfilgrastim-cbqv (Udenyca; procedure code Q5111), a granulocyte colony stimulating factor, will be restricted by diagnosis.
How this impacts providers: Providers should refer to the current Texas Medicaid Provider Procedures Manual, Outpatient Drug Services Handbook, subsection 7.19, “Colony Stimulating Factors (Filgrastim, Pegfilgrastim, and Sargramostim),” for a list of payable diagnosis codes for colony stimulating factors.
Next steps for providers: Prescribers should adjust their prescribing patterns accordingly and share this update with their staff.
If you have any questions, please email Provider Network Management at: email@example.com.